Solid Tumor Targeting CAR-T Development Service with FITC-Folate Adapter Switch

The FITC-Folate Adapter Switch represents an innovative strategy to enhance the precision and controllability of CAR-T cell therapy for solid tumors by dynamically bridging folate receptor-positive tumor cells with FITC-specific CAR-T cells. Creative Biolabs' Solid Tumor Targeting CAR-T Development Service with FITC-Folate Adapter Switch creates adaptable and safer CAR-T solutions. Our platform offers distinct advantages, including tunable T cell activity, reduced risks of on-target off-tumor toxicity and cytokine release syndrome, and the flexibility of real-time intervention using folate or fluorescein competitors.

Introduction

The FITC-Folate Adapter System, exemplified by EC17, is a bispecific small molecule adapter formed by the covalent conjugation of folic acid to FITC, enabling simultaneous targeting of folate receptor (FR)-expressing tumor cells and FITC-specific CAR-T cells. Functioning as a molecular bridge in CAR-T immunotherapy, this system directs T cells with precision to recognize and eliminate FR-positive tumors. It not only enhances the targeting specificity and controllability of CAR-T therapy in solid tumors but also mitigates toxicity risks, such as T cell exhaustion and cytokine release syndrome, through strategies like adapter dose titration and competitive dissociation.

Fig.1 Chemical Structure and Design of EC17 CAR-T Adaptor Molecule (folate-FITC).¹

Solid Tumor Targeting CAR-T Development Service with FITC-Folate Adapter Switch at Creative Biolabs

Creative Biolabs' Solid Tumor Targeting CAR-T Development Service with FITC-Folate Adapter Switch delivers precise, reversible control over T cell activity. By utilizing low molecular weight adapters, we enable rapid activation termination and cytokine modulation within hours. Moreover, our adaptable design allows retargeting to diverse tumor antigens, ensuring enhanced safety and reduced on-target/off-tumor risk.

What We Can Offer

We offer an integrated platform for developing controllable CAR-T therapies against solid tumors, featuring a fully humanized anti-FITC CAR design, high-affinity folate-FITC adapter, and rigorous in vitro validation systems to ensure precision targeting, tunable activity, and enhanced safety.

Our Service Process

Required Starting Materials:

• Target Receptor Data: Detailed expression and distribution data for the solid tumor target (e.g., Folate Receptor expression levels in specific tumor types).
• CAR Construct Sequence: Full sequence and vector information for your T cell receptor (e.g., anti-FITC scFv and signaling domains).
• Adaptor Chemistry Details: Information on the desired linker or specific bispecific adapter molecule structure (if pre-existing).

Key steps:

Final Deliverables:

• Adaptor Molecule Quality Control Report: Detailed chemical characterization (structure, purity, stability) of the adaptor.
• CAR-T Efficacy and Phenotyping Report: Comprehensive data on T cell viability, CAR expression level, cytotoxicity, and phenotype.

Key Advantages

• Custom Adaptor Molecule Design & Synthesis: We offer custom engineering of the bispecific adaptor, including optimization of the FITC-Folate structure, or the design of entirely new chemically programmable switches for unique tumor targets and control mechanisms.
• Rapid Reversibility Validation Platform: Specialized, high-throughput kinetic assays to definitively prove the system's ability to rapidly terminate T cell activity, providing the critical safety data required for subsequent trials.

FAQ

Why Choose Us?

We deliver robust, controllable CAR-T solutions for solid tumors by integrating our proprietary FITC-folate adapter switch. Our expertise ensures precise, spatiotemporal control and precise mechanistic validation, moving beyond standard designs to enable enhanced safety and confidence for complex therapeutic programs.

Customer Reviews

"Using Creative Biolabs' Solid Tumor Targeting CAR-T Development Service in our research has significantly improved the validation of our adaptor's sub-3-hour CRS termination capability. This level of kinetic analysis was unavailable internally and was crucial for de-risking our trial design" Sa***ha D.

"Leveraging Creative Biolabs' chemistry expertise through their Solid Tumor Targeting CAR-T Service was instrumental in the successful synthesis and stability assessment of our novel photocleavable adaptor molecule. They delivered a linker that exhibits exceptional robustness for in vivo applications while retaining rapid, light-triggered cleavage kinetics." Al***ex K.

How to Contact Us?

Leverage our advanced switchable CAR platform to enhance the safety profile of your lead candidate and streamline its clinical translation. Connect with our specialists to explore collaborative opportunities for your program.

Reference

1. Lu, Yingjuan J et al. "Preclinical Evaluation of Bispecific Adaptor Molecule Controlled Folate Receptor CAR-T Cell Therapy with Special Focus on Pediatric Malignancies." Frontiers in oncology vol. 9 151. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.3389/fonc.2019.00151.